Press Release

Ronda Horstman, Vice President, Donor Services, has received the distinct honor and high privilege of being elected to the position of Chairperson-Elect of the American Association of Tissue Banks (AATB) Board of Governors.  The AATB is a professional, non-profit, scientific and educational organization that is dedicated to improving and saving lives by promoting the safety,…

December 1, 2017 at 5:04 PM EST ATLANTA, Dec. 1, 2017 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of JOTEC AG, a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts,…

November 6, 2017 at 5:04 PM EST ATLANTA, Nov. 6, 2017 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that enrollment has started in the Company’s BioGlue clinical trial in China.  The results from the trial will serve as the basis of the Company’s regulatory submission…

October 30, 2017 at 5:30 PM EDT ATLANTA, Oct. 30, 2017 /PRNewswire/ — Third Quarter and Recent Highlights: Announced Definitive Agreement to Acquire JOTEC Accelerated Enrollment in PerClot Clinical Trial Achieved Third Quarter Revenues of $44.0 Million Achieved GAAP Net Income of  $1.3 million, or $0.04 Per Fully Diluted Common Share; Non-GAAP Net Income of $2.6 Million, or $0.08 Per Fully Diluted Common Share…

October 17, 2017 at 5:04 PM EDT ATLANTA, Oct. 17, 2017 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2017 third quarter financial results will be released on Monday, October 30, 2017 after the market closes.  On Tuesday, October 31, 2017, the Company will hold a teleconference…

Visit JOTEC   Provides Access into $2 Billion Global Stent Graft Market with Highly Competitive Technologically Advanced Product Portfolio Adds Robust New Product Pipeline and Significantly Enhances R&D Capabilities Accelerates European Direct Strategy and Meaningfully Expands Cross-Selling Opportunities Expected to Drive High Single-Digit Revenue Growth with Gross Margin and Operating Margin Expansion Conference Call and…

CryoLife, Inc. (NYSE: CRY), announced today that results from the On-X aortic heart valve PROACT study will be presented in a late-breaking session at the American Association for Thoracic Surgery (AATS) Centennial Meeting, which is being held April 29 to May 3, 2017 at the Hynes Convention Center in Boston, MA. Study Title: A Prospective…

ATLANTA, Jan. 20, 2016 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of On-X Life Technologies Holdings, Inc. (“On-X”), an Austin, Texas-based, privately held mechanical heart valve company. About CryoLife Headquartered in suburban Atlanta, Georgia,…